financetom
Business
financetom
/
Business
/
KKR drops out of Thames Water rescue deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
KKR drops out of Thames Water rescue deal
Jun 2, 2025 11:55 PM

LONDON (Reuters) -Britain's Thames Water said U.S. private equity firm KKR had pulled out from a plan to invest billions of pounds into the embattled utility, putting its fight to avoid financial collapse back into focus.

The company, which is Britain's biggest water supplier with 16 million customers, has been struggling with huge debts, and was banking on KKR investing over 3 billion pounds of new equity to keep it operating.

"KKR has indicated that it will not be in a position to proceed," Thames Water said in a statement on Tuesday.

Chairman Adrian Montague said on Tuesday that the development was "disappointing" and that the company would now proceed with discussions with senior creditors', who have put forward their own alternative plan for the company.

Thames Water could face temporary government nationalisation if it fails to recapitalise.

The company is at the centre of a public backlash against the water sector which is blamed for polluting Britain's river and seas while also hiking bills.

An overhaul of the way the industry is regulated was proposed by a government-commissioned review in its interim report published on Tuesday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Actuate Therapeutics Identifies Biomarkers in Treatment of Metastatic Pancreatic Cancer in Phase 2 Trial
Actuate Therapeutics Identifies Biomarkers in Treatment of Metastatic Pancreatic Cancer in Phase 2 Trial
Jun 20, 2025
09:17 AM EDT, 06/20/2025 (MT Newswires) -- Actuate Therapeutics ( ACTU ) said Friday that its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer demonstrated the use of machine learning and statistical models to predict overall survival based on pre-dose plasma biomarkers. The analysis identified seven biomarkers as uniquely significant predictors of favorable survival...
BlackBerry's Valuation to Remain Discounted on 'Conservative' Guidance, RBC Says
BlackBerry's Valuation to Remain Discounted on 'Conservative' Guidance, RBC Says
Jun 20, 2025
09:16 AM EDT, 06/20/2025 (MT Newswires) -- BlackBerry's (BB) conservative guidance has set the bar low for fiscal Q1 earnings and the company's valuation is likely to remain discounted, pending improved visibility to sustained growth, RBC Capital Markets said in a Friday note. The company's fiscal Q1 results could exceed RBC's and consensus estimates, as the macro environment has been...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Update: Lilly to Appeal Against UK Regulator's Recommendation Not to Reimburse Cost of Alzheimer's Drug
Update: Lilly to Appeal Against UK Regulator's Recommendation Not to Reimburse Cost of Alzheimer's Drug
Jun 20, 2025
09:26 AM EDT, 06/20/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Thursday it was planning to appeal against the UK's National Institute for Health and Care Excellence's, or NICE's, decision not to reimburse the cost of Alzheimer's drug Kisunla under the National Health Service. The drugmaker said the regulator's decision is unreasonable based on the evidence submitted by...
Copyright 2023-2026 - www.financetom.com All Rights Reserved